Digestive Disease Center announces this request for application (RFA) in collaboration with the Clinical and Translational Science Institute of Southeast Wisconsin (CTSI) to promote integration of research into GI clinical practice. The fundamental goal of this RFA is to encourage development of new patient-centered models for delivery of Gastroenterological care. Applications are expected to be innovative, outcome driven and have the potential to measurably and meaningfully improve delivery of care to patients with digestive diseases in terms of clinical quality, patient experience, value and efficiency i.e. delivering higher quality care faster and more cost effectively. Applications are also expected to take full advantage of a multidisciplinary approach to develop the appropriate Research Product Lines (RPL) comprised of needed experts to develop the new model and test it against current practice.
3-4 applications will be selected for funding up to $70,000.
Funds will be provided to proposals with strengths in the following areas:
Additionally, this grant is intended to fund the formation of RPLs to solve important clinical problems. Therefore, the applications will be reviewed with a focus on:
Research Product Lines are anticipated to incorporate the following principles in their operations – Collaboration, Transformation, Facilitation and Education. CTSI will provide a research project coach to each awarded product line to support the team in navigating this award.
Research Product is defined as the outcome of investigation into a clinical problem. This outcome may include improved process, facilitated access, improved patient satisfaction, new diagnostic or therapeutic modalities; cheaper, faster and better diagnostic or treatment outcomes.
Research Product Line is defined as a team of investigators comprised of clinicians, patients, patient advocates, clinical staff and others with relevant complementary disciplines aiming to develop a well-defined research product. This team is envisioned to be inter- or trans-disciplinary and include those with the expertise necessary to deliver the research product. DDC and CTSI seek to encourage applicants to take advantage of available expertise in the continuum of care and related disciplines such as: nursing, social scientists, ethicists, biostatisticians, informatics specialists, human factors specialists, patients, patient advocates, industrial engineers and other members of clinical care delivery teams in developing the Research Product Line.
* This program has an accelerated nature and only a 12 month funding period. If your project requires working with federal agencies such as NIDA, FDA (e.g., IND, IDE applications) or pharmacological agreements (e.g., clinical trial agreements, material transfer agreements), you must contact the CTSI Pilot Translational and Clinical Studies Program Director, Ramona Tenorio, PhD at 414-955-2537, prior to applying.
** Investigative team with members from more than one of the CTSI Partner institution (MCW, UWM, MU, MSOE, CHW, BRI, VA, FMLH).
National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) RESTRICTION OF CLINICAL ACTIVITY BEYOND THE END OF PHASE IIA: In accordance with section 479(b) of the Public Health Service Act (as amended by the Consolidated Appropriations Act, 2012, Public Law 112-74), NCATS is authorized to use fiscal year 2015 funds to provide infrastructure and resources for all phases of clinical trials research, but can only support clinical trials through the end of Phase IIA (with the exception of certain clinical trial activities involving treatment of a rare disease or condition). However, all phases of clinical trials may utilize infrastructure and resources provided through the CTSA.
The Clinical and Translational Science Institute will convene a special review panel comprised of members with expertise in clinical science to manage the review process and assign reviewers. Each application will be reviewed by a minimum of 2 reviewers.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to lead to an improved delivery of healthcare through the development of a Research Product Line (RPL). Consideration of the following program specific review criteria should be given:
Please download and complete all of the documents prior to completing full application.
For MCW investigators or any application with an MCW collaborator, applications must be routed through the Office of Grants & Contracts (GCO) no later than 5 business days before the submission deadline in this RFA.
Different departments and institutions may have different deadlines for obtaining departmental approvals prior to receipt by the Office of Grants & Contracts.